Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Knight Therapeutics submitted a supplemental regulatory application to ANVISA for MINJUVI (tafasitamab) as a first-line treatment for DLBCL and HGBL in Brazil.
FDA approved Gilead’s Bixlenvo™ (bictegravir/lenacapavir) as a once-daily single tablet regimen for virologically suppressed adults with HIV, including those on complex regimens.
FHLBank Chicago provided a $1 million Affordable Housing Program (AHP) grant to convert the historic Earle School into 50 affordable rental units in Chicago’s Englewood neighborhood.
